Olanzapine monotherapy for acute depress
β
William V. Bobo; Richard A. Epstein; Richard C. Shelton
π
Article
π
2010
π
John Wiley and Sons
π
English
β 90 KB
π 1 views
## Abstract We evaluated the efficacy, tolerability, and safety of olanzapine monotherapy in 20 adult patients with bipolar I or II disorder, depressed phase. Patients received openβlabel olanzapine monotherapy (mean modal dose, 15βmg/day) for 8 weeks. Assessments of psychopathology (MontgomeryβAsb